Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
C4 Therapeutics, Inc. - Common Stock
(NQ:
CCCC
)
6.640
+0.580 (+9.57%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about C4 Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
C4 Therapeutics: Q3 Earnings Insights
November 03, 2022
C4 Therapeutics (NASDAQ:CCCC) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
October 11, 2022
Upgrades
Via
Benzinga
Recap: C4 Therapeutics Q2 Earnings
August 04, 2022
C4 Therapeutics (NASDAQ:CCCC) reported its Q2 earnings results on Thursday, August 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
C4 Therapeutics: Q1 Earnings Insights
May 05, 2022
C4 Therapeutics (NASDAQ:CCCC) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
September 19, 2022
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
Via
Benzinga
Where C4 Therapeutics Stands With Analysts
April 28, 2022
Within the last quarter, C4 Therapeutics (NASDAQ:CCCC) has observed the following analyst ratings:
Via
Benzinga
C4 Therapeutics's Return On Capital Employed Insights
August 22, 2022
According to Benzinga Pro data, during Q2, C4 Therapeutics (NASDAQ:CCCC) posted sales of $13.83 million. Earnings were up 13.31%, but C4 Therapeutics still reported an overall loss of $27.41 million.
Via
Benzinga
C4 Therapeutics's Return On Capital Employed Overview
May 27, 2022
C4 Therapeutics (NASDAQ:CCCC) brought in sales totaling $7.65 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 101.94%, resulting in a loss of $31.62 million.
Via
Benzinga
C4 Therapeutics Doses First Patient in Phase 1/2 Trial of CFT8634 For SMARCB1-perturbed cancers
May 16, 2022
C4 Therapeutics, Inc. (C4T) (NASDAQ: CCCC) has dosed the first patient in the Phase 1/2 clinical trial of its drug candidate CFT8634, for the treatment of SMARCB1-perturbed cancers, including synovial...
Via
Benzinga
31 Stocks Moving In Monday's Mid-Day Session
May 02, 2022
Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) climbed 64.9% to $9.86. Redbox recently reported CFO transition. SoundHound AI, Inc. (NASDAQ: SOUN) shares gained 30.5% to $8.48...
Via
Benzinga
66 Biggest Movers From Yesterday
May 03, 2022
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
April 28, 2022
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 19, 2022
Gainers Checkmate Pharmaceuticals (NASDAQ:CMPI) shares increased by 331.5% to $10.4 during Tuesday's pre-market session. The market value of their outstanding shares...
Via
Benzinga
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
April 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
BMO Capital Maintains Outperform Rating for C4 Therapeutics, Lowers Price Target To $20
April 11, 2022
BMO Capital has decided to maintain its Outperform rating of C4 Therapeutics (NASDAQ:CCCC) and lower its price target from $57.00 to $20.00. Shares of C4 Therapeutics are trading down 20.49% over the...
Via
Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
April 10, 2022
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.
Via
Benzinga
Why C4 Therapeutics Stock Is Plunging Today
April 08, 2022
C4 Therapeutics Inc (NASDAQ: CCCC) shares are trading significantly lower Friday afternoon after the company presented data from Cohort A of its ongoing Phase 1/2 clinical...
Via
Benzinga
C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial
April 08, 2022
C4 Therapeutics Inc (NASDAQ: CCCC) has presented data from Cohort A of its ongoing Phase 1/2 trial of CFT7455 for multiple myeloma (MM) and non-Hodgkin's lymphomas (NHL).
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
April 08, 2022
Gainers Phio Pharma (NASDAQ:PHIO) shares increased by 46.7% to $1.33 during Friday's regular session. As of 13:31 EST, Phio Pharma's stock is trading at a volume...
Via
Benzinga
28 Stocks Moving In Friday's Mid-Day Session
April 08, 2022
Gainers Lyra Therapeutics, Inc. (NASDAQ: LYRA) shares climbed 33.3% to $5.78 as the company reported a private placement for gross proceeds of $110.5 million. TSR, Inc. (NASDAQ...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
April 08, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
April 06, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2022
March 10, 2022
Upgrades For Alpha Metallurgical Resources Inc (NYSE:AMR), B. Riley Securities upgraded the previous rating of Neutral to Buy. For the fourth quarter, Alpha Metallurgical...
Via
Benzinga
51 Biggest Movers From Yesterday
April 06, 2022
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares surged 148.2% to close at $5.61 on Tuesday after the company announced that two of its designed mRNA molecules are...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022
February 10, 2022
Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,...
Via
Benzinga
87 Biggest Movers From Yesterday
March 10, 2022
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares jumped 150% to close at $3.80 on Wednesday. Sunshine Biopharma, last month, priced its 1.88 million unit uplisting to...
Via
Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
March 09, 2022
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) rose 148% to $3.78. Sunshine Biopharma, last month, priced its 1.88 million unit uplisting to Nasdaq at $4.25 per unit. Direct...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 23, 2021
November 23, 2021
Upgrades Keefe, Bruyette & Woods upgraded the previous rating for CBRE Group Inc (NYSE:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
October 14, 2021
Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
September 30, 2021
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),...
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.